Patent Expirations an Important Driver in the Biosimilar Market
TechNavio today published its report Global Biosimilar Market 2010-2014. The report discusses the current and future landscape of this market.

Commenting on the report, an analyst from TechNavio's Healthcare team said, "The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved strain vendors' resources and dilute the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to contract manufacturing organizations (CMOs) and clinical research organizations (CROs) that have already gained proficiency in the field of manufacturing biosimilar products."
Key findings from the report:
* Limited Availability of Biosimilar Products
* Huge Investments Required in R&D
* Uncertainty with Regard to Government Regulations
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic reports on niche and emerging technologies. For further information, please visit http://technavio.com/content/global-biosimilar-market-2010-2014
Follow us on Twitter @ Technavio
Media Contact:
Ludmila Berkesova
Program Manager
Technavio
8 Wimpole Street
W1G 9SP London UK
Tel: 0044 207 637 2456
Fax: 0044 845 280 2825
ludmila@technavio.com
http://www.technavio.com
###
Tag Words:
None
Categories: Business